Why Do Clinical Trials Fail? (Part 1)

Clinical trials fail. That is a fact of life as a recent study (2015, Clinical Development Success Rates for Investigational Drugsfound that 90 percent of drugs that reach clinical stage development never make it to FDA approval and commercialization. Only half of all drugs are rejected during the process and fail due to a lack of efficacy.

In fact, many drug development programs are derailed by setbacks that are often unrelated to a drug’s mechanism of action or efficacy. 

A lot of trials fail because of the way the trial was run. Trials are very complex and you may not get the outcome you expected.

However, usually a clinical trial fails because it is mismanaged. It may not have been planned well, staff may have cut corners or team members were not properly trained among other reasons.

Generally though, clinical trials fail often but most of these reasons are reversible.

DLTA is a clinical trial management tool. It is intuitive and can work within your limitations. We know why most clinical trials fail and have designed our management tool to eliminate them. Project managers don’t have to now everything now as the tool takes care of that. DLTA has automated much of the management process of a clinical trial.

DLTA helps in the planning, administration and execution of clinical trials. Drug Lifecycle Tracking Application maps the end-to-end drug approval process. It offers a one stop shop to manage Drug Lifecycle and Regulatory Review process. Call us at (240) 753-8282.